Compounded GLP-1 medications are made with the drug in the branded products but are not the same products. This guide explains what's actually different, what isn't, and what changes with FDA shortage and enforcement status.
What they have in common
- The drug they are made with. Compounded semaglutide is made with the drug in Wegovy and Ozempic, and compounded tirzepatide with the drug in Zepbound and Mounjaro, but they are not the same products.
- How the molecule works. The mechanism is the same; the trial results (STEP, SURMOUNT) were measured with the branded products, not with compounded versions.
- Expected side effects. Prescribers expect similar side effects at similar doses, but compounded products have not been studied in trials and dosing errors with vials and syringes are a known risk (FDA).
What's different
- FDA approval status. Branded products are FDA-approved finished drugs. Compounded products are prepared by licensed pharmacies under federal exceptions (503A or 503B). Not FDA-approved as finished products.
- Manufacturing standards. Branded: cGMP. 503B outsourcing facilities: also cGMP. 503A traditional compounding: USP standards but not cGMP.
- Concentration and excipients. Branded use specific manufacturer formulations. Compounded may use different concentrations, different excipients, sometimes adjuncts (B12) not present in branded.
- Device. Branded: calibrated pen injectors with dose dialing. Compounded: typically vials + insulin syringes.
- Pricing. Branded list prices exceed $1,000 a month, but manufacturer self-pay prices are lower (for example Zepbound KwikPen $299–$449 and Wegovy pen $349 a month, read October 15, 2026); insurance changes the math. Compounded is typically cash pay: across the programs in our price table, the lowest all-in monthly figure ran $39–$249 for semaglutide and $86–$299 for tirzepatide (reads of October 15 and November 6, 2026).
- Regulatory stability of supply. Branded supply is manufacturer-controlled and stable. Compounded supply is subject to FDA shortage rules and state pharmacy oversight.
When to prefer branded
- Insurance coverage makes branded affordable.
- Your indication is a specific FDA-approved label (Wegovy CV, Zepbound OSA) and you want the regulator-blessed label.
- You prefer the calibrated pen injector experience.
- Working with a specialist who prefers branded for clinical reasons.
When compounded is reasonable
- Cash-pay (no coverage, high deductible, or excluded coverage).
- Comfortable with the 503A/503B regulatory framework and have verified your provider's pharmacy partners.
- Accept the trade-off of not having FDA-approved finished-product status.
How to evaluate a compounded provider
- Are pharmacy partners named (not just "U.S. compounding pharmacy")?
- Is 503A or 503B classification disclosed?
- What standards (USP <797>, USP <85>) are referenced?
- Is third-party batch testing mentioned (especially for 503B lots)?
- Is clinical oversight (licensed clinician) clearly described?
For an example of strong pharmacy disclosure, see our NexLife review.
Frequently asked questions
Is compounded tirzepatide or semaglutide FDA-approved?
No: compounded tirzepatide and compounded semaglutide are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are sold, according to FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, which we read on November 21, 2026. They are made with the drug in Zepbound or Wegovy but are not the same product. A licensed 503A pharmacy may compound them for an individual prescription. FDA proposed in April 2026 to keep both off the 503B bulks list; no final decision was found as of November 20, 2026.